CA2597229A1 - Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic - Google Patents

Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic Download PDF

Info

Publication number
CA2597229A1
CA2597229A1 CA002597229A CA2597229A CA2597229A1 CA 2597229 A1 CA2597229 A1 CA 2597229A1 CA 002597229 A CA002597229 A CA 002597229A CA 2597229 A CA2597229 A CA 2597229A CA 2597229 A1 CA2597229 A1 CA 2597229A1
Authority
CA
Canada
Prior art keywords
kefiranofaciens
lactobacillus kefiranofaciens
lactobacillus
group
subsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002597229A
Other languages
English (en)
French (fr)
Inventor
Pierre Lemieux
Louis-Philippe Precourt
Eric Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TECHNOLOGIE BIOLACTIS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2597229A1 publication Critical patent/CA2597229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
    • A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA002597229A 2005-02-11 2006-02-10 Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic Abandoned CA2597229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65165705P 2005-02-11 2005-02-11
US60/651,657 2005-02-11
PCT/CA2006/000206 WO2006084381A1 (en) 2005-02-11 2006-02-10 Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic

Publications (1)

Publication Number Publication Date
CA2597229A1 true CA2597229A1 (en) 2006-08-17

Family

ID=36792883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002597229A Abandoned CA2597229A1 (en) 2005-02-11 2006-02-10 Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic

Country Status (8)

Country Link
US (2) US20090130072A1 (https=)
EP (1) EP1853284B1 (https=)
JP (2) JP5401733B2 (https=)
CA (1) CA2597229A1 (https=)
DK (1) DK1853284T3 (https=)
ES (1) ES2496965T3 (https=)
MX (1) MX2007009659A (https=)
WO (1) WO2006084381A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
US20110002994A1 (en) * 2007-10-02 2011-01-06 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact
JP2010037225A (ja) * 2008-08-01 2010-02-18 Nippon Kefia Kk 乳清ケフィアを有効成分として含んでなる体脂肪減少剤
JP2012034616A (ja) * 2010-08-06 2012-02-23 Umeya Co Ltd 塩たらこの製造方法及び塩たらこ、並びに辛子明太子の製造方法及び辛子明太子
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
KR101779719B1 (ko) 2016-08-30 2017-09-19 건국대학교 산학협력단 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물
CN106937745A (zh) * 2016-08-31 2017-07-11 快醒生物科技（北京）有限公司 一种具有改善肠道功能的保健品及其制备方法
JP7482494B2 (ja) * 2016-11-01 2024-05-14 慶應義塾 Ｔｈ１細胞を誘導する細菌
KR102089938B1 (ko) * 2016-12-21 2020-03-17 (주)프로스테믹스 케피어 그레인 유래 미세소포체의 용도
KR101930143B1 (ko) * 2016-12-21 2018-12-17 건국대학교 산학협력단 유산균 유래 세포외다당류를 함유하는 항균 조성물
JP7542798B2 (ja) * 2017-08-10 2024-09-02 株式会社Ｎｒｌファーマ 妊娠中の母子の健康状態改善剤
US10632161B1 (en) 2019-05-23 2020-04-28 Prostemics Co. Ltd. Method for ameliorating or treating a bowel disease
CN111575202A (zh) * 2020-05-19 2020-08-25 北京科拓恒通生物技术股份有限公司 一株用于预防辅助治疗ⅱ型糖尿病的干酪乳杆菌及其应用
CN111808910A (zh) * 2020-07-22 2020-10-23 南京农业大学 一种评价膳食多糖活性的方法
KR20220061555A (ko) * 2020-11-06 2022-05-13 (주)프로스테믹스 신규한 락토바실러스 속 균주 및 상기 균주 유래 세포외 소포의 용도
JP7696856B2 (ja) * 2022-03-31 2025-06-23 よつ葉乳業株式会社 ケフィアグレイン類似物の作出方法並びにケフィアグレイン類似物を用いた発酵乳の製造方法
CN114805474B (zh) * 2022-04-02 2024-03-22 中国海洋大学 一株干酪乳杆菌fn345及其在制备预防辅食期婴儿腹泻菌剂中的应用
CN116948916B (zh) * 2023-08-11 2024-06-11 四川大学 一种干酪乳杆菌及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
JPH05301812A (ja) * 1992-04-23 1993-11-16 Sansho Seiyaku Co Ltd 皮膚外用剤
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020182274A1 (en) * 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
JP2002330798A (ja) * 2001-05-11 2002-11-19 Yamato Yakuhin Kk 多糖製造方法
ES2451618T3 (es) * 2001-12-20 2014-03-28 Biolactis Inc. Matriz de proteína maleable y usos de estas

Also Published As

Publication number Publication date
EP1853284A4 (en) 2012-03-21
ES2496965T3 (es) 2014-09-22
MX2007009659A (es) 2008-01-16
EP1853284B1 (en) 2014-04-09
WO2006084381A1 (en) 2006-08-17
JP2013139462A (ja) 2013-07-18
US20090130072A1 (en) 2009-05-21
JP5401733B2 (ja) 2014-01-29
DK1853284T3 (da) 2014-07-14
EP1853284A1 (en) 2007-11-14
US20140193383A1 (en) 2014-07-10
JP2008530034A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
US20140193383A1 (en) Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic
CN105733983B (zh) 分离的微生物菌株格氏乳杆菌mcc2 dsm 23882及其用途
JP5147402B2 (ja) 膣健康改善のためのプロバイオティックラクトバチルス株
CA2434035C (en) Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
CA2227497C (en) Enteral dietary compositions comprising streptococcus thermophilus and bifidobacterium longum
US20040057943A1 (en) Probiotic strains, a process for the selection of them, compositions thereof, and their use
AU2002214486A1 (en) Use of a strain of Lactobacillus reducing the risk factors involved in the metabolic syndrome
CN102123718A (zh) 消化道运动性病症的治疗
WO2006093022A1 (ja) 免疫機能調整剤
Abd El-Gawad et al. Inhibitory effect of yoghurt and soya yoghurt containing bifidobacteria on the proliferation of Ehrlich ascites tumour cells in vitro and in vivo in a mouse tumour model
WO2012081650A1 (ja) 遅延型過敏症軽減剤
Brunser et al. Functional fermented milk products
Elshaghabee Impact of oral administration of Karish cheese on reduction of the risk of non-alcoholic fatty liver disease in rats fed high fructose diet
Sánchez García et al. Technological and probiotic selection criteria of a bile-adapted Bifidobacterium animalis subsp. lactis strain

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150716